دورية أكاديمية
PD06 Efficacy of dupilumab in chronic actinic dermatitis
| العنوان: | PD06 Efficacy of dupilumab in chronic actinic dermatitis |
|---|---|
| المؤلفون: | O’Reilly, Marese, Paolino, Alexandra, Salam, Amr, Pathmarajah, Pirunthan, Ferguson, John, Dawe, Robert S, Sarkany, Robert, Smith, Catherine S, Pink, Andrew E, Fassihi, Hiva, Ibbotson, Sally |
| المصدر: | British Journal of Dermatology ; volume 188, issue Supplement_4 ; ISSN 0007-0963 1365-2133 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Dermatology |
| الوصف: | Chronic actinic dermatitis (CAD) is characterized by a photoexposed site dermatitis in association with objective evidence of photosensitivity, often arising on a background of atopic dermatitis (AD). Dupilumab is a monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13 and is licensed for the management of moderate-to-severe AD. To date, nine case reports have suggested that dupilumab can be clinically effective for CAD, yet only five cases had diagnostic baseline phototesting and only two cases could demonstrate objective improvement in photosensitivity on repeat testing. We report a retrospective case series from two UK photobiology units of 11 patients with concomitant AD and CAD treated with dupilumab. Inclusion criteria included baseline phototesting with an irradiation monochromator device confirming a diagnosis of CAD < 3 years prior to starting dupilumab, phototesting repeated after at least 16 weeks on dupilumab and all patients included were refractory or intolerant to at least one other systemic therapy prior to dupilumab. Eleven patients [82% male, median age 40 years (range 21–59) at diagnosis] of skin phototypes I–V were included. All patients had a pre-existing diagnosis of AD before the onset of CAD, and two patients also had a pre-existing diagnosis of allergic contact dermatitis. The average duration of dupilumab therapy prior to repeat phototesting was 15 months (range 4–44). Ten of 11 (91%) patients reported improvement in their AD in terms of both rash and pruritus. Five of 11 patients (45%) reported partial improvement in their subjective photosensitivity of whom two showed ultraviolet B monochromator improvement (3- to 6-fold). Six of 11 (55%) patients reported no clinical change in photosensitivity of whom two showed no improvement or worsening on phototesting; while four showed improvements, they remained in the severely photosensitive range on phototesting. While dupilumab is an effective therapy for moderate-to-severe AD, its potential benefit in ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/bjd/ljad113.344 |
| الإتاحة: | https://doi.org/10.1093/bjd/ljad113.344Test https://academic.oup.com/bjd/article-pdf/188/Supplement_4/ljad113.344/50698834/ljad113.344.pdfTest |
| حقوق: | https://academic.oup.com/pages/standard-publication-reuse-rightsTest |
| رقم الانضمام: | edsbas.BC7D1C00 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/bjd/ljad113.344 |
|---|